# Targeting Eukaryotic Elongation Factor 1A: How Small-Molecule Inhibitors Suppress Tumor Growth via Diverse Pathways

## TL;DR

This paper explores how small-molecule inhibitors targeting eEF1A suppress tumor growth through various pathways beyond protein synthesis.

## Contribution

The study provides a systematic review of diverse mechanisms by which eEF1A-targeting inhibitors act beyond protein synthesis inhibition.

## Key findings

- eEF1A-targeting inhibitors disrupt tumor growth via multiple pathways beyond protein synthesis.
- A systemic survey of eEF1A-targeting agents reveals their multifaceted modes of action.
- Understanding these mechanisms can guide the development of future eEF1A-targeted cancer drugs.

## Abstract

Eukaryotic elongation factor 1A (eEF1A), the second most abundant intracellular protein, not only plays a key role in peptide elongation, but is also capable of numerous moonlighting functions. Within malignant cells, eEF1A is by no means a neutral bystander but instead actively participates in oncogenic transformations via a myriad of molecular pathways. Thus far, a broad range of small-molecule inhibitors have been identified, which, despite their structural diversity, suppress tumor growth by targeting eEF1A. Interestingly, just as eEF1A enables its oncogenic potential far beyond boosting protein translation, these targeted agents disrupt this oncoprotein via multiple axes distinct from mere protein synthesis inhibition. Whereas the oncogenic mechanisms of eEF1A has been well documented, there lacks a systemic survey of the eEF1A-targeting agents in terms of their mechanisms. Accordingly, the present work aims to examine their multifaceted modes of action more than just blocking protein synthesis. By unveiling these insights, our deepened knowledge of these eEF1A-binding inhibitors will inform the development of future eEF1A-targeted drugs for cancer treatment.